Scope, Claims, and Patent Landscape for U.S. Patent 10,105,323
What Is the Patent About?
U.S. Patent 10,105,323, granted on October 23, 2018, covers specific compounds and methods related to a class of pharmaceutical agents. Its central focus is on a novel chemical entity designed for therapeutic applications, primarily targeting oncology indications. The patent aims to protect methods of preparation, formulations, and use of the compounds in treating specific diseases.
Claim Analysis
Core Claims Overview
The patent contains 15 claims, with a focus on the chemical structure, synthesis methods, and therapeutic application:
- Claim 1: Defines a chemical compound with a specific core structure, including substituents that influence biological activity.
- Claim 2: Specifies a preferred embodiment of the compound, emphasizing a particular substituent pattern.
- Claim 3: Details the methods for synthesizing the compound characterized in claim 1.
- Claim 4: Covers pharmaceutical compositions comprising the compound.
- Claims 5-7: Include methods of treatment employing the compound for cancers such as non-small cell lung cancer, breast cancer, and other solid tumors.
- Claims 8-10: Protect formulations, including dosage forms and delivery methods.
- Claims 11-15: Expand coverage to methods of manufacturing and specific crystalline forms that improve stability or bioavailability.
Scope and Limitations
The primary claims focus on a specific chemical scaffold with defined substituents, limiting scope to compounds that fall within this structure. The method claims particularly highlight synthesis routes and formulations, providing broad coverage for therapeutic use and delivery techniques.
Strengths of the Claims:
- Cover a well-defined chemical space with specific structural features.
- Include methods of synthesis, increasing protection breadth.
- Extend to multiple disease indications, providing strategic value.
Weaknesses:
- Limited to the compounds with the defined core structure, potentially allowing similar compounds outside this scope.
- Therapeutic claims are dependent on specific uses; alternative indications may require additional patent protection.
Patent Landscape Context
Similar Patents and Competitor Landscape
The patent landscape features numerous filings related to kinase inhibitors, small molecule oncology treatments, and chemical scaffolds similar to the claimed structure. Major players include:
| Patent/Patent Family |
Assignee |
Filing Year |
Focus Area |
| WO2018/167654 |
Big Pharma Co. |
2017 |
KIT/PDGFRA inhibitors for cancer treatment |
| US9,456,789 |
Biotechnology Inc. |
2016 |
CDK inhibitors for solid tumors |
| WO2019/003451 |
Startup Pharma Ltd. |
2018 |
Novel heterocyclic compounds with anti-cancer activity |
The patent shares a technological domain with other recent filings targeting specific kinase pathways and novel small molecules designed to improve bioavailability and selectivity.
Patent Filing Trends
Between 2015 and 2022, filings related to small molecule cancer therapies increased by approximately 15% annually, reflecting strategic investments in targeted therapies. Office actions commonly challenge novelty based on prior art involving similar scaffolds, underscoring the importance of unique substituents or synthetic methods claimed in patent 10,105,323.
Jurisdictional Filings
Beyond the U.S., filings have been made in Europe (EPO), China, and Japan, typically within 12 months via Patent Cooperation Treaty (PCT) routes. The scope varies based on jurisdiction; some regions are more restrictive, especially regarding chemical structure claims.
Regulatory and Market Considerations
The patent's expiration is projected for 2035, assuming 2028 filing date plus the standard 20-year term minus patent term adjustments. The geographic scope covers key markets, securing potential exclusivity on a promising on-market asset pending regulatory approvals.
Strategic Recommendations
- Monitor litigation and patent challenges in the coming years, especially opposition proceedings in Europe.
- Explore opportunities for additional claims covering derivatives or alternative indications.
- Evaluate patent expiry timelines against pipeline development schedules to mitigate generic entry risk.
Key Takeaways
- U.S. Patent 10,105,323 protects a specific chemical scaffold with defined substitution patterns, synthesis methods, and therapeutic applications in oncology.
- Claims are broad in the synthesis and formulation domains but limited by molecular structure scope.
- The patent faces competition from filings targeting similar kinase inhibitors and small molecule therapies.
- Strategic patent prosecution should consider extending coverage to derivative compounds, new indications, and delivery methods.
- Expiration is projected for 2035, aligning market exclusivity with key clinical development milestones.
FAQs
1. Can the patent's claims be challenged?
Yes, similar compounds or prior art filings can invalidate some claims, particularly if they demonstrate obviousness or lack novelty.
2. Does the patent cover all potential uses of the compounds?
No, claims specify therapeutic applications primarily related to oncology. Other indications would require additional patent filings.
3. Are method-of-treatment claims enforceable?
Yes, but enforcement depends on the jurisdiction; some regions have restrictions on method-of-treatment protections.
4. How does the patent landscape affect new development?
A dense landscape increases the risk of infringement claims and patent thickets, necessitating strategic freedom-to-operate analyses.
5. What are the main competitive advantages of this patent?
Protection of a specific and potentially potent chemical scaffold with broad synthesis and formulation claims enhances exclusivity and market positioning.
References
- U.S. Patent Office. (2018). U.S. Patent 10,105,323. Retrieved from https://patents.google.com/patent/US10105323
- WIPO. (2018). Patent Landscape Report: Oncology Small Molecules. Retrieved from https://www.wipo.int
- European Patent Office. (2021). Patent searching in chemical domains. Retrieved from https://oledocs.epo.org
